Research To Practice | Oncology Videos

Latest Episodes:

Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore (Companion Faculty Lecture) Feb 09, 2026

Show notes

Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics:

Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00)
Targeting folate receptor alpha with mirvetuximab soravtansine (3:59)
Targeting TROP2 with ADCs (9:12)
Targeting folate receptor alpha with ADCs (14:17)
Targeting cadherin-6 with ADCs (17:27)
Targeting HER2 with ADCs (26:12)
Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)

CME information and select publications

Localized Colorectal Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium Feb 07, 2026

Show notes

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

Introduction (0:00)
Neoadjuvant Treatment for Localized Colorectal Cancer (CRC) — Dr Seligmann (2:39)
Emerging Novel Approaches to Adjuvant Treatment for Localized CRC — Dr Lieu (33:18)
Role of Circulating Tumor DNA Testing in Localized CRC — Dr Cohen (59:43)

CME information and select publications

Immune Thrombocytopenia — ASH 2025 Review Feb 06, 2026

Show notes

Featuring perspectives from Dr Hanny Al-Samkari, Dr Cindy Neunert and Prof Francesco Zaja, including the following topics:

Introduction (0:00)
Case: A woman in her early 30s with chronic relapsing immune thrombocytopenia (ITP) receives eltrombopag with ongoing stabilization of platelet counts — Neil Morganstein, MD (2:03)
Case: A woman in her late 60s with a long history of ITP controlled by eltrombopag experiences acute exacerbations — Bhavana (Tina) Bhatnagar, DO (6:42)
Clinical Manifestations and Initial Management of ITP — Dr Neunert (18:07)
Case: A woman in her early 80s with metastatic adenocarcinoma of the lung who responded to carboplatin/pemetrexed/pembrolizumab presents with ITP after 14 months of maintenance pembrolizumab — Susmitha Apuri, MD (33:14)
Incorporation of Thrombopoietin Receptor Agonists and Other Second-Line Therapies into ITP Management — Prof Zaja (40:19)
Case: A woman in her late 60s with stress cardiomyopathy and corticosteroid-refractory ITP receives rituximab followed by eltrombopag — Eric Fox, DO (1:00:44)
Current and Future Role of Novel Therapies in ITP — Dr Al-Samkari (1:03:47)

CME information and select publications

Urothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 Review Feb 05, 2026

Show notes

Featuring an interview with Dr Terence Friedlander, including the following topics:

Final analysis of the Phase III, open-label, randomized POTOMAC trial (0:00)
KEYNOTE-905 trial: Perioperative enfortumab vedotin with pembrolizumab for muscle-invasive bladder cancer (MIBC) (5:25)
The neoadjuvant gemcitabine intravesical system TAR-200 for patients with MIBC: Primary analysis of the SunRISe-4 trial (14:07)
Circulating tumor DNA-guided therapies for MIBC (18:41)

CME information and select publications

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review Feb 03, 2026

Show notes

Featuring an interview with Dr Sagar Lonial, including the following topics:

KLN-1010: A novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor T cells (0:00)
Phase III DREAMM-7 and DREAMM-8 studies of belantamab mafodotin-based combination therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM) (5:37)
Effectiveness of ciltacabtagene autoleucel for patients with R/R MM (11:04)
Low-dose tocilizumab for mitigation of the cytokine release syndrome associated with bispecific antibodies (16:04)
Talquetamab with teclistamab for patients with R/R MM in Phase Ib of the RedirecTT-1 trial (19:24)

CME information and select publications

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium Feb 02, 2026

Show notes

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:

Introduction (0:00)
HER2-Targeted Approaches for Advanced Gastroesophageal Cancers — Dr Ajani (2:02)
Faculty Panel Discussion: Cases and Questions from the Community (14:13)
Targeting Claudin 18.2 in Advanced Gastroesophageal Cancers — Dr Strickler (37:29)
Faculty Panel Discussion: Cases and Questions from the Community (49:21)
Optimal Incorporation of Immunotherapeutic Strategies into Treatment for Patients with Metastatic Gastroesophageal Tumors — Dr Mehta (1:09:56)
Faculty Panel Discussion: Cases and Questions from the Community (1:22:02)
Other Novel Agents and Strategies Under Evaluation for Advanced Gastroesophageal Cancers — Dr Klempner (1:44:23)

CME information and select publications

Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review Jan 29, 2026

Show notes

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00)
Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18)
Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14)

CME information and select publications

HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium Jan 28, 2026

Show notes

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics:

Introduction (0:00)
Biliary Tract Cancers — Dr Ellis (1:56)
Gastroesophageal Cancers — Dr Wainberg (24:27)
Colorectal Cancer — Prof Van Cutsem (59:13)

CME information and select publications

Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series Jan 27, 2026

Show notes

Featuring perspectives from Dr Angela DeMichele, Dr Komal Jhaveri, Dr Erica Mayer, Dr Hope S Rugo and Dr Seth Wander, including the following topics:

Introduction (0:00)
1985 NCI Consensus Conference on Early Breast Cancer: Sir Richard Peto, FRS (2:01)
Current Role of Genomic Assays in Treatment Decision-Making for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr DeMichele (5:13)
Case: A premenopausal woman in her mid 40s with an ER-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) after partial mastectomy/radiation therapy who enrolls in the prospective, observational FLEX study: MammaPrint® low risk — Laurie Matt-Amaral, MD, MPH (15:30)
Case: A premenopausal woman in her mid 40s after modified radical mastectomy for T2N0 ER-positive, HER2-negative IDC with an Oncotype DX® Recurrence Score (RS®) of 19 — Swati Vishwanathan, MD Case: A woman in her mid 60s with locally advanced (19 cm) ER-positive, HER2-low (IHC 1+) Stage IIIB mucinous carcinoma breast cancer and an RS of 18 — Alan B Astrow, MD (22:40)
Role of CDK4/6 Inhibitors and Other Novel Strategies in Therapy for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Jhaveri (30:18)
Case: A woman in her mid 50s with ER-positive, HER2-negative Stage IIB, T2N1 IDC after neoadjuvant dose-dense AC-T, lumpectomy and adjuvant radiation therapy — Eleonora Teplinsky, MD (42:14)
Case: A woman in her mid 60s with ER-positive, HER2-negative breast cancer with a surgically removed solitary lung metastasis after 4 years of adjuvant letrozole — Eric Fox, DO (46:32)
Evolving Up-Front Treatment Paradigm for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Rugo (49:45)
Case: A woman in her early 80s with Type 2 diabetes, well controlled hypertension and recurrent ER-positive, HER2-negative mBC after 4 years of adjuvant letrozole — Sunil Gandhi, MD (1:02:30)
Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr Mayer (1:06:37)
Case: A woman in her late 60s with ER-positive, HER2-low (IHC 1+), PIK3CA-mutant mBC with disease progression after 2 years of adjuvant letrozole — Laila Agrawal, MD (1:20:22)
Case: A woman in her early 60s with ER-positive, HER2-low PIK3CA-mutant mBC and disease progression on first-line palbociclib/fulvestrant — Dr Teplinsky (1:26:36)
Results from the Global Phase III lidERA Breast Cancer Trial of Giredestrant versus Standard Endocrine Therapy as Adjuvant Treatment for ER-Positive, HER2-Negative Localized Breast Cancer (1:31:48)
Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (1:42:30)
Case: A woman in her early 100s with locally advanced ER-positive, HER2-negative breast cancer with disease progression on letrozole, now with an ESR1 mutation — Dr Astrow (1:57:51)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 1 Jan 23, 2026

Show notes

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

Case: A man in his early 60s with metastatic urothelial bladder cancer (mUBC) and medical history of tobacco use receives first-line enfortumab vedotin (EV) and pembrolizumab with excellent response after 3 cycles — Dr Fahey (0:00)
Case: A woman in her early 80s with tumor mutational burden-high mUBC receives pembrolizumab with complete response and later discontinues after developing Grade 1 pneumonitis has no further evidence of disease — Dr Anari (9:19)
Case: A man in his early 70s with mUBC who received single-agent EV develops neuropathy and hyperglycemia — Dr Anari (19:10)

CME information and select publications